secwatch.observer — SEC 8-K summary
======================================

Issuer:     CUMBERLAND PHARMACEUTICALS INC (CPIX)
CIK:        0001087294
Form:       8-K
Filed at:   2023-04-04T23:59:59+00:00
Accession:  0001628280-23-010469
Event type: regulatory
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA grants barrier-to-innovation waiver; Cumberland to receive ~$1.9M refund for RediTrex fees
--------------------------------------------------------------------------------

- FDA reversed prior denial and granted barrier-to-innovation waiver on March 30, 2023, after reconsideration request.
- Refund of approximately $1.9 million in prescription drug program fees for RediTrex expected within 45 days.
- Waiver tied to Cumberland's ifetroban clinical programs addressing unmet medical needs.
- Original $1.9M fee paid Oct 4, 2021; initial denial Nov 1, 2021; reconsideration filed Nov 28, 2021.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1087294/000162828023010469/0001628280-23-010469-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1087294/000162828023010469/cpix-20230404.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-010469

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer